DRAVP
  1. Home
  2. Browse
  3. Clinical peptide
DRAVP ID Name Description Disease Pubchem ID
DRAVPc011 Oglufanide(IM862, Glufanide) Oglufanide is a synthetic dipeptide immunomodulator composed of L-glutamic acid and L-tryptophan joined by a peptide linkage and in development for the treatment of chronic hepatitis C viral infection. Oglufanide was originally developed to treat severe infectious disease in Russia (where it is a registered pharmaceutical), and was extensively studied in cancer clinical trials in the United States before being acquired by Implicit Bioscience in 2005. Oglufanide works as a regulator of the body's immune response, is being given by intranasal administration to patients with chronic hepatitis C viral infection. Chronic HCV infection 100094
DRAVPc012 Telaprevir Telaprevir is an oligopeptide consisting of N-(pyrazin-2-ylcarbonyl)cyclohexylalanyl, 3-methylvalyl, octahydrocyclopenta[c]pyrrole-1-carboxy, and 3-amino-N-cyclopropyl-2-oxohexanamide residues joined in sequence. Telaprevir is an orally available peptidomimetic small molecule with activity against hepatitis C virus (HCV). Telaprivir is a selective protease inhibitor that targets the viral HCV NS3-4A serine protease and disrupts processing of viral proteins and formation of a viral replication complex. Chronic HCV infection 3010818
DRAVPc013 Atazanavir Atazanavir is an aza-dipeptide analogue with a bis-aryl substituent on the (hydroxethyl)hydrazine moiety. Atazanavir is an antiretroviral protease inhibitor that is used in the therapy and prevention of human immunodeficiency virus (HIV-1) infection and the acquired immunodeficiency syndrome (AIDS). The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. HIV infection 148192
DRAVPc014 Peginterferon alfa-2a Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Peginterferon alfa-2a is available as a fixed dose injector (tradename Pegasys) used for the treatment of chronic Hepatitis C. Approved in 2002 by the FDA, Pegasys is indicated for the treatment of HCV with Ribavirin or other antiviral drugs Chronic HCV infection, Chronic HBV infection 46504860
DRAVPc015 Interferon alfa-n1 Interferon alfa-n1 is a purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus. It consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. HIV infection 46506227
DRAVPc016 Interferon alfa-n3 Interferon alfa-n3 is a purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus. Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD). HIV infections, SARS infection 46508902
DRAVPc017 Peginterferon alfa-2b Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).It is approved in 2001 by the FDA, Pegintron is indicated for the treatment of HCV with Ribavirin or other antiviral drugs. Chronic HCV infection 46506669
DRAVPc018 Interferon gamma-1b Interferon gamma-1b is a form of recombinant human interferon used to treat infections associated with Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV). Chronic HCV infection, HIV infection 46507194
DRAVPc019 Interferon beta-1a Interferon beta-1a is a form of recombinant human interferon which could used for the treatment of COVID-19. COVID-19 46504899
DRAVPc020 Interferon beta-1b Interferon beta-1b is a form of recombinant human interferon used to slow the progression of relapsing multiple sclerosis and to reduce the frequency of clinical symptoms. HIV infection, COVID-19 46504458
First 1 2 3 4 5 6 7 Last
CC0 To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.